Illumina's Q4 Profit Falls Despite Topline Growth Of 26%


Illumina Inc ILMN reported Q4 revenues of $1.19 billion, +26% Y/Y, beating the consensus of $1.13 billion.

  • Product revenues were $1.07 billion, up 28%, and service & other revenues were $133 million, up 9%.
  • "We are seeing strength across our business as a growing number of patients around the world are accessing the life-saving benefits of genomics, from oncology therapy selection to genetic disease testing and pathogen surveillance," said Illumina CEO Francis deSouza. 
  • "In addition, momentum for Grail's groundbreaking multi-cancer early detection blood test continues to accelerate," added Francis deSouza.
  • Illumina's Q4 adjusted EPS was $0.75, beating analysts' consensus of $0.49 and down from $1.22 posted a year ago.
  • The adjusted gross margin improved to 71.5% from 66.9%.
  • The company finished Q4 with $1.3 billion in cash and equivalents.
  • Guidance: Illumina expects FY22 revenue growth of 14% - 16%. At the J.P. Morgan Healthcare Conference, Illumina projected sales of $5.15 billion - $5.24 billion for FY22, compared to the consensus of $5.01 billion.
  • It forecasts adjusted EPS of $4.00 - $4.20 (consensus $4.20).
  • The company expects Core Illumina revenue growth of 13% - 15%. GRAIL revenue is expected to be $70 million - $90 million.
  • Price Action: ILMN shares closed lower by 2.66% at $358.08 on Thursday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!